teneligliptin + alpha-glucosidase inhibitor

Teneligliptin + alpha-glucosidase inhibitor is an **oral fixed-dose combination therapy** for type 2 diabetes mellitus, involving the DPP-4 inhibitor **teneligliptin** and an **alpha-glucosidase inhibitor** (drug examples include acarbose, voglibose, or miglitol). Teneligliptin works by inhibiting the enzyme dipeptidyl peptidase-4, enhancing endogenous incretin hormones, leading to increased insulin secretion and decreased glucagon secretion in a glucose-dependent manner. Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates by inhibiting alpha-glucosidase enzymes in the intestine, reducing postprandial blood glucose spikes. The combination targets both **fasting and postprandial hyperglycemia** and is used in patients with inadequate glycemic control on monotherapy or dual oral agents. Clinical data suggest the combination improves HbA1c without substantial added risk of hypoglycemia and is generally weight-neutral[1][2][3][4][5].